

Metabolic Syndrome is Associated with Worse 6-month Outcomes of Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

David Brosh, Abid Assali, Igal Teplitzky, Hana Vaknin-Assa, Shmuel Fuchs, Eli Lev, Avital Porter, David Hasdai, Eldad Rechavia, Alexander Battler, Ran Kornowski
Cardiology, Cardiac Catheterization Laboratories, Rabin Medical Center, Petach Tikva, Israel

Background: Metabolic syndrome is associated with increased risk of cardiovascular events. Recent studies have shown that it is highly prevalent among young patients with acute myocardial infarction (AMI), and it is not associated with increased risk of restenosis in patients undergoing elective percutaneous coronary intervention (PCI). However, only limited data are available on the effect of metabolic syndrome on long-term outcomes of unselected patients undergoing primary PCI for AMI.

Method and Results: We used our database of all pts (n=1336) undergoing primary PCI for AMI between 1/2001 and 7/2007, excluding those with cardiogenic shock and late arrivals (>12hrs from symptoms onset to 1st balloon inflation). Metabolic syndrome was defined according the WHO clinical criteria as: diabetes type-II or impaired fasting glucose ($\geq 110\text{mg/dL}$) plus any 2 of the following criteria: HTN (on medical treatment) or systolic BP $\geq 140\text{mmHg}$ or diastolic BP $\geq 90\text{mmHg}$; Trig $\geq 150\text{mg/dL}$; HDL $< 35\text{mg/dL}$ in men or HDL $< 39\text{mg/dL}$ in women; BMI $> 30\text{kg/m}^2$. Patients (n=833) were allocated into 2 groups: 1st Group (n=674 pts) included those without metabolic syndrome and 2nd Group (n=159 pts) included those with metabolic syndrome. Patients' clinical and angiographic characteristics as well as 6-month outcomes are shown in **Table:**

	No Metabolic Syndrome	Metabolic Syndrome	P Value
N	674	159	
Age	60 \pm 13	61 \pm 11	0.6
Male (%)	83	75	0.02
Anterior AMI (%)	49	43	0.4
2-3 Vessel CAD (%)	54	68	0.001
Renal failure(GFR< 60) (%)	12	20	0.005
CADILLAC score	4.3 \pm 3.6	4.1 \pm 3.4	0.6
Initial TIMI Flow 0-1 (%)	1.3	1.3	0.99
Anti GP 2B/3A (%)	78	76	0.8
Final TIMI Flow 3 (%)	96	96	0.7
No/Slow Reflow incl. transient (%)	5.6	7	0.6
Six Months			
Death (%)	4.4	6.9	0.3
Re-MI (%)	5.9	8.9	0.2
Stent thrombosis (%)	2.8	6.3	0.03
TLR / CABG (%)	8.2 / 4.3	11.3 / 6.9	0.1 / 0.2
MACE (%)	15.3	23.3	0.007

Conclusion: Metabolic syndrome in patients undergoing primary PCI for AMI was associated with increased risk of stent thrombosis, resulted in worse 6-month outcomes.

Timing of Percutaneous Coronary Intervention of the Non-Culprit Artery in Patients with Multivessel Disease and Acute Myocardial Infarction

Itzik Ben-Dor, Ran Kornowski, Paz Kedem, Shmuel Fuchs, Hana Vaknin-Assa, Eldad Rechavia, David Brosh, Eli Lev, Tamir Bental, Alexander Battler, Abid Assali

Cardiology, Rabin Medical Center, Petach Tikva, Israel

Background: The role and timing of complete revascularization of non-infarct related artery [n-IRA] after STEMI is controversial

Objective: To compare n-IRA outcomes between different PCI timing strategies of n-IRA

Methods: We used our clinical Database consisting 145 consecutive patients with multivessel disease ($\geq 70\%$ stenosis of ≥ 2 coronary arteries) treated by primary PCI within 12 hours of chest pain for AMI. Patients with cardiogenic shock were excluded. Patients were subdivided in 3 groups: 1) patients undergoing PCI of the non-IRA during initial procedure 2) patients undergoing PCI of the non-IRA in hospitalization 3) patients undergoing PCI of the non-IRA during 6-months [operator's discretion: clinical, anatomic, or stress testing].

Results: The study included 145 patients with multivessel disease who underwent PCI of the non-IRA during the first 6 month. Clinical characteristic and 6 months are summarized:

	Group I (Initial) N=38	Group II (Hospitalization) N=36	Group III (within 6-moths) N=71	P-value
Age (years)	66±15	68±12	62±10	0.06
Males (%)	76	81	82	0.8
GFR (<60 mL/min/1.73 m ²) (%)	26	22	14	0.6
Killip class >1 (%)	27	29	16	0.2
Anterior MI (%)	55	33	45	0.3
Diabetes (%)	34	48	37	0.4
No reflow-culprit (%)	5	15	7	0.3
Successful PCI-culprit (%) [†]	97	91	92	0.7
Ejection fraction <40% (%)	55	43	49	0.6
CADILAC risk score	6.1±3.9	6.4±4	5.5±3.5	0.4
6-monhs outcome				
Death (%)	10.5	14	3	0.08
Re-AMI (%)	10.5	11	13	0.9

[†] TIMI 3 and residual stenosis <30%,

Conclusions: Our preliminary data suggest that deferring PCI of n-IRA in AMI patients with multivessel is preferred in suitable cases based on clinical and anatomic consideration.

The Effect of Baseline Platelet Count on Outcomes in Patients with Acute Myocardial Infarction Undergoing Primary PCI

Igal Teplitsky, Abid Assali, Eli Lev, David Brosh, Hana Vaknin-Assa, Itsik Ben-Dor, Shmuel Fushs, Nurit Shor, Alexander Battler, Ran Kornowski

Cardiology, Rabin Medical Center, and the Sackler Faculty of Medicine, Tel-Aviv University, Petach Tikva, Israel

Background: Platelets may impact the thrombosis outcomes in the acute myocardial infarction (AMI). There are few data regarding the impact of platelet count (PC) on clinical outcomes of patients undergoing emergent PCI during STEMI. This study aimed at evaluating the impact of baseline (PC) on clinical outcomes among patients treated by primary PCI for AMI.

Methods and Results: we used our data consisting of all patients treated by primary PCI (≤ 12 hours) for AMI between excluding pts with cardiogenic shock. The clinical results of treated pts studied, distinguished according to quartiles of baseline PC are shown in the accompanied **Table**:

Platelet Count 10^9	<210 (N=232)	≥ 210 -<246 (N=232)	≥ 246 -<298 (N=233)	PC ≥ 298 (N=234)	P
Age (yes)	61 \pm 12	62 \pm 13	59 \pm 13	60 \pm 12	0.1
Male	87%	82%	83%	77%	0.04
Diabetes mellitus	20%	28%	28%	25%	0.2
Hyperlipidemia	49%	53%	45%	43%	0.2
Hypertension	45%	41%	48%	49%	0.3
MV disease	59%	60%	58%	55%	0.9
Killip Class>1	13%	16%	16%	19	0.7
Anti GP 2B/3A	79%	77%	77%	75%	0.8
6-months events					
Death	3.2%	5.8%	5.8. %	7.9%	0.1
Re-MI	6.3%	6.7%	3.5%	7.9%	0.8
Stent Thrombosis	2.7%	2.2%	2.2%	6.6%	0.04
TVR	10.9%	8.5%	6.6%	13.6%	0.07
CABG	6.3%	6.3%	3.1%	3.5%	0.2
MACE	18.6%	17.9%	15.9%	21%	0.5

Conclusion: Patients with higher baseline PC who were treated on emergent basis using primary PCI for STEMI had higher 6 months rates of stent thrombosis and also tended to have higher TVR. It remains to be determined the exact platelet-derived mechanism which may be responsible for this observed phenomenon.

Human Plasma Corin Level as a Predictor of Major Cardiovascular Events Post PCI

Diab Ghanim, Aviva Peleg, Ahmad Suliman, Daood Qarawanny, Yonathan Hasin
Cardiovascular, Cardiology, Baroch Padeh Hospital, Tiberias, Israel

Background: Corin is a Type II transmembrane protease responsible for the cleavage of Pro-ANP to ANP and Pro-BNP to BNP.

ANP and BNP have vasodilatory and antiproliferative functions, and may confer protective effect against atherosclerosis.

In a previous study we found that plasma corin level is significantly higher in atherosclerotic patients compared to healthy volunteers (Abstract 3741:Human serum corin levels in healthy and atherosclerosis. *Circulation* 2007;116:II_850-II_851).

The assay of plasma corin level in the human was developed in our institution.

Hypothesis: Plasma corin level measured pre-PCI can predict major adverse cardiovascular events in long term follow up.

Methods and results: 98 atherosclerotic patients in whom plasma corin levels was measured pre-PCI were followed between two to three years for MACE. Forty six patients suffered from MACE (mortality, re-infarction, angina pectoris, recurrent revascularization, CVA/TIA). Plasma corin level was significantly lower in the MACE group compared to the non-MACE group (729 pg/ml, Std error 39 vs 849 pg/ml, Std error 45, $P=0.05$ by unpaired t test). By multivariate analysis corin was an independent predictor of MACE.

Conclusion: Plasma corin level can predict long term MACE in coronary artery disease patients post-PCI.

Outcome of Emergency Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction Complicated by Cardiac Arrest

Aviv Mager^{1,2}, Ran Kornowski^{1,2}, Daniel Morninakas^{1,2}, Hana Vaknin-Assa^{1,2}, Shimrit Urkabi¹,
David Brosh^{1,2}, Alexander Battler^{1,2}, Abid Assali^{1,2}

¹ Cardiology Department, Catheterization Laboratories, Rabin Medical Center, Petah Tikva,

² Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Background: The poor prognosis of primary percutaneous coronary intervention (PCI) in patients resuscitated from cardiac arrest complicating acute ST-elevation myocardial infarction (STEMI) may be at least partly explained by the common presence of cardiogenic shock. We examined the effect of emergency primary PCI on outcome in patients without cardiogenic shock who were resuscitated from cardiac arrest before the procedure.

Methods: The study group included 948 consecutive patients who underwent emergency primary PCI at our medical center from 2001 to 2006 for STEMI not complicated by cardiogenic shock. Twenty-one were resuscitated from cardiac arrest before the intervention. Data on background, clinical characteristics, and outcome were prospectively collected in all the patients.

Results: There were no differences between resuscitated and non-resuscitated patients in age, sex, infarct location, or left ventricular function. The total one-month mortality rate was higher in the resuscitated patients (14.3% vs 3.4%, $p=0.033$), but noncardiac mortality accounted for the entire difference (14.3% vs 1.2%, $p=0.001$), whereas cardiac mortality was similarly low in the two groups (0% vs 2.0%, $p=NS$). Predictors of poor outcome in the resuscitated patients were older age ($r=0.47$, $p=0.032$), unwitnessed sudden death ($r=0.44$, $p=0.04$), longer interval from cardiac arrest to arrival of a mobile unit ($r=0.67$, $p=0.001$) or to spontaneous circulation ($r=0.65$, $p=0.001$), low glomerular filtration rate ($r=-0.50$, $p=0.02$), and the initial Thrombolysis in Myocardial Infarction grade of flow ($r=-0.51$, $p=0.017$).

Conclusions: In patients with STEMI not complicated by cardiogenic shock, emergency PCI exerts a similar beneficial effect on cardiac mortality in those who were resuscitated from cardiac arrest and in those without this complication. The higher mortality rate in among resuscitated patients is explained by noncardiac complications.

Twenty Years of Out-of-Hospital Resuscitations The SHL Experience in Israel

Edo Birati¹, Nomi Malov², Yevgeni Kogan³, Yigal Yanay², Mira Tamari², Mayera Elizur²,
David Steinberg⁴, Michal Golovner², Arie Roth^{2,3,5}

¹ Internal Medicine B, Sapir Medical Center, Kfar Saba, ² 'SHL' - Telemedicine,
³ Department of Cardiology, Sourasky Medical Center, ⁴ Department of Statistics and
Operations Research, ⁵ Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

Background: The Magen David Adom 1988 report on resuscitation outcome of out-of-hospital cardiac arrest victims in Israel revealed that 17% of them were admitted to hospital of whom 7% were discharged alive from hospital. The most common heart rate recorded upon arrival of the Mobile Intensive Care Unit (MICU) at the scene was asystole or severe bradycardia.

Objective: To report the 1987-2007 experience of resuscitation of out-of-hospital cardiac arrest victims, who were 'SHL' subscribers, by SHL-Telemedicine MICU teams.

Methods: The medical records, including MICU reports and reports by MICU physicians containing specifics of CPR maneuvers and outcome of patients who underwent resuscitation, were analyzed. In addition, each patient who had been resuscitated and transported to hospital was followed by telephone calls and report of hospital discharge or expiration in the hospital.

Results: A total of 1810 patients (67% males) with a mean age of 76±12 years (16-104) were resuscitated. One-third (597, 33%) were admitted to hospital and 279 (15.4%) were discharged alive. Factors associated with successful resuscitation included witnessed collapse and ventricular defibrillation. A history of heart failure, diabetes, hyperlipidemia, stroke or advanced age adversely affected results. Noteworthy, transtelephonic instructions for basic CPR were given to and performed by laymen on 121 patients of whom 13 (10%) survived to hospital discharge.

Conclusions: The knowledge of the availability of the SHL-Telemedicine call center for prompt response in the setting of out-of-hospital sudden collapse enabled witnesses to summon rapid medical assistance for victims by directly contacting the SHL call center.

The Relationship of Plasminogen Activator Inhibitor-1 Levels to the ST Deviation Pattern of Acute Myocardial Infarction

David Rott¹, David Leibowitz¹, Zvezdana Finci-Yeheskel², Vivian Barak³, Tova Chajek-Shaul¹,
Teddy Weiss¹, Mark Levin², Simcha Urieli-Shoval²

¹ *Medicine, Cardiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel,*

² *Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel,* ³ *Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel*

Background: Myocardial infarction (MI) may be classified as ST elevation MI (STEMI) or non ST elevation MI (NSTEMI). In STEMI the culprit artery is usually completely occluded by a thrombus, whereas in NSTEMI it is usually patent with a non-occlusive thrombus. Pro-coagulants such as Plasminogen activator inhibitor-1 (PAI-1) as well as markers of inflammation such as C-reactive protein (CRP), serum amyloid A (SAA) and interleukin-6 (IL-6) are elevated in acute coronary syndromes however, no study has examined whether levels of these markers differ in patients with STEMI as opposed to NSTEMI.

Objective: To determine whether there are differences in plasma levels of PAI-1, CRP, SAA or IL-6 in patients with STEMI as compared to patients with NSTEMI.

Methods: Consecutive 76 patients presenting with an acute MI (37 with STEMI and 39 with NSTEMI) were prospectively enrolled. Blood samples were obtained from patients within 6 hours from presentation and plasma PAI-1, CRP, IL-6 and SAA concentrations were measured.

Results: Plasma levels of PAI-1 were significantly higher in patients with STEMI as compared to NSTEMI: 85.7 ± 5 vs 61.3 ± 5 ng/ml ($p < 0.001$), while CRP, SAA and IL-6 levels were not significantly different in STEMI as compared to NSTEMI.

Conclusions: Higher plasma PAI-1 levels in STEMI patients may contribute to the predilection of these patients to occlusive thrombi and STEMI.

Serum Anti CRP Antibodies, CRP and Coronary Atherosclerosis in Patients with Acute Coronary Syndromes

Yacov Shacham, Uri Rogovski, Gad Keren, Sofia Maysel-Auslender, Jacob George
Cardiology Department, Sourasky Medical Center, Tel Aviv, Israel

Background: Serum **CRP** concentrations levels are correlated with the presence and severity of **CHD**. Anti **CRP** antibodies were first described in 1985 in the sera of patients with different rheumatic conditions, including 23% of **SLE** patients.

A positive correlation was demonstrated between anti **CRP** antibodies and **SLE** activity, yet the relation between anti **CRP** antibodies and **CHD** have not been established

We tested the presence and potential association of anti-**CRP** antibodies with **CRP** and with the incidence and extent of coronary atherosclerosis in patients with acute coronary syndromes (**ACS**)

Methods: between September 2004 and December 2005 we collected the sera of 324 patients admitted to the hospital due to **ACS** and underwent cardiac catheterization, and tested the levels of **CRP** and anti- **CRP** antibodies. The extent of coronary vessel disease was assayed from admission cardiac catheterization.

We also prospectively evaluated major cardiac events in this population 24 months post admission

Results : We observed a direct association between **hsCRP** levels and the extent of coronary atherosclerosis. Interestingly, we have found a negative correlation between antibodies to **CRP** and vessel affliction. There was also an inverse correlation between circulating anti **CRP** levels and **hsCRP** levels. Neither **hsCRP** nor antibodies to **CRP** predicted **MACE** in the **ACS** patients over a two year follow up period.

Conclusions: This is the first description of antibodies to **CRP** in patients with **ACS**. It appears that anti **CRP** antibodies are inversely correlated with **hsCRP** levels and with coronary atherosclerosis. The significance of this finding remains to be elucidated.

Shortcuts:

CRP- C Reactive Protein

hsCRP- High Sensitive **CRP**

CHD- Coronary Heart Disease

SLE – Systemic Lupus Erythematosus

ACS- Acute Coronary Syndrome

Pre Hospital Anti Platelet Regimen and Angiographic Predictors of Spontaneous ST Resolution in Acute ST Elevation Myocardial Infarction

Mohamed Jabaren¹, Desai Devang², Carol Chen Scarabelli², Howard Rosman², Yoav Turgeman¹

¹ *Heart Institute, Interventional Cardiology, Ha'Emek Medical Center, Afula, Israel,*

² *Cardiology Department, Cardiology, St. John Hospital, Detroit, USA*

Background:

The favorable outcome of Spontaneous ST segment resolution (STR) during acute ST elevation myocardial infarction (STEMI) is well known. However the predictors of this phenomenon are not well established.

Objectives:

To evaluate the role of pre hospital anti platelet treatment and angiographic predictors of STR in patients with acute STEMI prior to primary PCI.

Methods:

We conducted a retrospective chart review of all patients admitted with STEMI between January 2002 to June 2006. Pre hospital anti platelet therapy and angiographic data were collected.

Results:

Among 227 patients studied, 37 patients (16%) showed spontaneous STR. 12/227 (5%) deaths were reported, non of them belong to the STR group.

Pre hospital clopidogrel treatment was found to be an independent predictor for STR ($p=0.0488$, OR 2.10, 95% CI 1.00 to 4.40), however, GP IIb/IIIa inhibitors and aspirin were not found to be independent predictors of this phenomenon. Stepwise logistic regression analyses identified the following angiographic independent predictors of STR: single vessel disease ($p=0.0157$, OR 2.85, 95% CI 1.22 to 6.7), collaterals ($p=0.0020$, OR 4.28, 95% CI 1.70 to 10.80), circumflex culprit vessel ($p=0.0080$, 95% CI 1.49 to 14.97) and thrombus ($p=0.0065$, OR 5.76, 95% CI 1.63 to 20.39).

Conclusion:

Early clopidogrel treatment was found to be an independent predictor for STR. Patients with single vessel disease, collateral flow, thrombus and circumflex as the culprit vessel were more likely to have STR.

Primary Coronary Intervention Reduces the Incidence of Significant Mitral Regurgitation in Patients with Acute Inferior Myocardial Infarction

Mahmod Hammoud, Dawod Sharif, Uri Rosenschein

Cardiology, Bnai-zion Medical Center, Haifa, Israel

Ischemic mitral regurgitation (MR) is associated with worse outcome and increased mortality. Thrombolysis reduces the incidence of significant MR after first myocardial infarction. **Aim:** To test the hypothesis that primary percutaneous coronary intervention (PPCI) reduces the incidence of MR. **Methods:** Prospective study of **225** patients with first inferior myocardial infarction. PPCI was performed in **82 (36.4%)**, with pain to balloon time 5.3+3.4 hrs, thrombolytic therapy was administered to **93 patients (41.3%)**, with average pain to needle time 4.5+2.8 hrs and **50 (22.3%)** patients were managed without reperfusion therapy. Transthoracic Doppler-echocardiography was performed in all within 48 hrs, and repeated after 7-14 days in 198 patients, and at 30-45 days in 176 patients. MR grade ≥ 2 MR was considered significant. **Results:** The incidence of significant MR in all the subjects within 24 hours, 36 of 225 (16%) was similar to that at 7-14 days, 35 of 198 (18%), $p=ns$, but decreased after 30-45 days and at 21 of 176 subjects (12%), $p<0.05$. In patients with PPCI the incidence of significant MR at 24 hrs evaluation 2.7% was less than in those without PPCI, 13.3%, $p<0.002$. Evaluation at 7-14 days revealed lower incidence of MR in PPCI patients 2.5% vs 15.2% in those without, $p<0.001$. After 30-45 days MR incidence was 1.7% in PPCI patients compared to 13% without, $p<0.0001$. PPCI reduced the incidence of significant MR compared with thrombolysis, at 24 hrs, 2.7% vs. 5.3%, $p<0.012$, at 7-14 days 2.5% vs. 6.6%, $p<0.01$, and after 30-45 days 1.7% vs. 5.7%, $p<0.01$. In PPCI patients, MR grade 3 developed only in 2 compared to 11 patients in those without. **Conclusions:** PPCI reduces the incidence of significant MR in patients with first inferior myocardial infarction and was superior to thrombolysis.